The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy.
 
Florence Atrafi
Travel, Accommodations, Expenses - Abbvie
 
Oliver Boix
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Prabhu Rajagopalan
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Anthony W. Tolcher
Employment - New Experimental; START
Leadership - Symphony Evolution
Consulting or Advisory Role - AbbVie (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Elekta (Inst); EMD Serono (Inst); Formation Biologics (Inst); Genmab (Inst); Idea Pharma (Inst); Ignyta (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); Alexion Pharmaceuticals (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); TaiRx, Inc. (Inst)
 
Patricia LoRusso
Leadership - Agios; Five Prime Therapeutics; Halozyme; Roche/Genentech
Honoraria - Genentech/Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; CytomX Therapeutics; Genentech; Genentech; Genmab; Glenmark; Ignyta; Menarini; Novartis; Omniox; Takeda
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer; Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Joseph Paul Eder
Research Funding - AstraZeneca (Inst)
 
Kamalesh Kumar Sankhala
No Relationships to Disclose
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Vivek Subbiah
Consulting or Advisory Role - MedImmune
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; PharmaMar
 
Jennifer Robinson Diamond
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Casi Pharmaceuticals (Inst); Genentech/Roche (Inst); MedImmune (Inst); Millennium (Inst); OncoMed (Inst); Rexahn Pharmaceuticals (Inst); Scripps Hospital (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takeda; Takeda
 
Martin Gutierrez
Stock and Other Ownership Interests - COTA
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Foundation One Inc; Lilly; Merck
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Esanex (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst)
 
Ron H.J. Mathijssen
Research Funding - Astellas Pharma (Inst); Bayer Holding (Inst); Boehringer Ingelheim (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Jian Mei
Employment - Bayer
 
Jaap Verweij
Leadership - Octimet
Stock and Other Ownership Interests - Octimet
Honoraria - Novartis; Octimet; Sanofi; Sotio; XBiotech
Consulting or Advisory Role - Novartis; Sanofi; Sotio; XBiotech
 
Ingmar Bruns
Employment - Bayer; Pieris Pharmaceuticals
Leadership - Pieris Pharmaceuticals
Stock and Other Ownership Interests - Pieris Pharmaceuticals
 
Martijn P. Lolkema
Consulting or Advisory Role - Incyte (Inst); Johnson & Johnson (Inst)
Research Funding - Astellas Oncology (Inst); Johnson & Johnson (Inst); MSD Oncology (Inst); Sanofi (Inst)